Two Clip or Not Two Clip

Saibal Kar, MD, FACC, FAHA, FSCAI Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

> CRT 2014 February 22-25th, 2014



Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship

Grant/Research Support

- Consulting Fees/Honoraria
- Other Financial Benefit

Company

- Abbott Vascular, Boston Scientific, St Jude Medical, Circulite, Coherex, Gore, Biotronics
- Abbott Vascular, Boston Scientific, St Jude Medical, Gore
- Coherex, Biosensors International



Case Summary

Patient Demographics

- Age: 85 years old
- Gender: Male

Past Medical History

- Hyperlipidemia
- Hypertension
- Atrial fibrillation
- Prostate cancer

Past Surgical History

- Prostatectomy [1999]
- Surgical AVR [2006]


Clinical Presentation

 Shortness of breath (NYHA class III)




Baseline TTE







Baseline TTE





Baseline TEE





Baseline TEE





What we do

- Redo open heart surgery (STS score for repair was around 5 to 6%
- Consider MitraClip procedure
- Transcatheter Valve replacement



Case Summary


Procedural Strategy

Percutaneous mitral valve repair with MitraClip system.


Clinical Indication

Severe DMR (A2 flail) with NYHA class III.

























4 month follow-up TTE








4 month follow-up TTE






4 month follow-up TTE




4 month follow-up TEE






4 month follow-up TEE





4 month follow-up TEE





Case Summary


Procedural Strategy

Percutaneous mitral valve repair with MitraClip system.


Clinical Indication

Mitral valve dysfunction post MitraClip with NYHA class III.




















Case 2:

Clip or Transplant



Case summary

Patient: 45-year-old man

Clinical Presentation:

Shortness of breath (NYHA III) for 3 months

Past history


Non ischemic dilated cardiomyopathy for 12 years On optimal medical treatment (ACE, betablockers Diuretics, inspira.


- ✓ CRT-D implantation [2012]
- ✓ No admission of heart failure in last one year
- ✓ NPA level 481



Baseline TTE







Severe functional MR with LV dysfunction

- \checkmark EROA = 0.46 cm²
- ✓ LVEF = 23%, LVID d/s = 63/59 mm



Options

- Evaluation for heart transplantation
- Surgery for functional MR, since patient is very young
- Consider enrolling patient in COAPT trial
- Continue medical Rx and consider hospice





Follow up

- Patient decompensated and was admitted with hypotension and acute left heart failure.
- Started on Milirinone and dobutamine
- Transferred to Cedars for Heart transplantation (status IA), and LV assist device



Baseline TEE









"1st clip deployment"








"Post 1st clip deployment"






"2nd clip deployment"








"Post 2nd clip deployment"





"3rd clip deployment"







"Post 3rd clip deployment"



"Cardiac output increased from 2.9 to 3.7 L/min"



6 months later

- NYHA I to II
- Off the transplant list
- Back on most of his guideline directed medical therapy




Take home message

- MitraClip is safe and effective treatment of functional MR in end stage heart failure
- Do we really need the COAPT study



1 Month Follow-up





Conclusions

 MitraClip is a safe and effective transcatheter treatment options for selected patients with both degenerative and functional mitral regurgitation

